1. HBW Insight
  2. >>Ingredients & Safety

‘We Can’t Go Back In Time’: CIR Panel Grapples With Prostaglandins Review Without Animal Test Data

 
• By Lauren Nardella

In its safety assessment of two prostaglandin analogues, the Expert Panel for Cosmetic Ingredient Safety determined that certain read-across data from potentially related ingredients were not enough to extrapolate and apply to a prostaglandin review. This and more from the panel's 4-5 December meeting.

Animal testing of cosmetic ingredients has been almost completely eliminated globally, but validated, regulatory-accepted alternative methods continue to be lacking for certain endpoints, presenting challenges that were brought into relief at the 4-5 December meeting of Cosmetic Ingredient Review experts.

CIR’s Expert Panel for Cosmetic Ingredient Safety was tasked at the meeting with reviewing ethyl tafluprostamide (ET) and isopropyl cloprostenate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

UK FSA Issues New Guidelines For CBD And THC Max Levels

 
• By David Ridley

Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

Review Suggests Advantage Of Bayer’s Iberogast Advance For Digestive Disorders

 
• By David Ridley

Bayer's Iberogast Advance's combination of six herbal ingredients may produce a synergistic effect that acts on multiple underlying issues contributing to digestive disorders like functional dyspepsia (FD) and irritable bowel syndrome (IBS), a recently published study suggests.

More from HBW Insight

AstaReal Launches Membralife Supplement Following CEO Change

 
• By Tom Gallen

Designed to help moisturize the body’s mucous membranes, the Membralife supplement is now available in Sweden. The launch comes with AstaReal now under new management following the appointment of Daniel Flodqvist as CEO.

Haleon Survey Finds Brits Not Paying Enough Attention To Gum Health

 
• By David Ridley

Gum health awareness among British consumers could be better, a recent Haleon survey finds.

UK FSA Issues New Guidelines For CBD And THC Max Levels

 
• By David Ridley

Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.